|
Vital distress
|
- Immediately and as soon as possible:
|
| |
- Administer icatibant (Firazyr®): 30 mg subcutaneously or
|
| |
- plasma-derived C1-INH (Bérinert®): 20 UI/kg intravenously
|
| |
- Switch the call to the local SAMU to send French EMS
|
| |
- Gain control of upper airway
|
|
Severe attacks
|
- Immediately and as soon as possible:
|
|
Laryngeal
|
- Administer icatibant (Firazyr®): 30 mg subcutaneously or
|
|
Facial
|
- plasma-derived C1-INH (Bérinert®): 20 UI/kg intravenously
|
|
Abdominal
|
- If treatments are unavailable at home, switch the call to the local SAMU to send an ambulance headed towards a hospital with specific treatments available or being able to get them by French EMS
|
| |
- Gain control of upper airway
|
|
Non-severe attacks (members, genitals)
|
- Tranexamic acid: 1 g/6 h except for patients who are breastfeeding or have thromboembolic pathology
|
|
Surveillance in all cases
|
Monitoring by phone 30 min, 1 h, 4 h, 12 h and 24 h after the beginning of the attack
|
| |
Advice to call back SOS-HAE call centre in case of secondary worsening
|
